Laboratorios Farmaceuticos Rovi, S.A. (LABFF)
USD 90.61
(0.0%)
USD 90.61
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 256.39 Million EUR | -28.25% |
| 2022 | 357.32 Million EUR | 36.54% |
| 2021 | 261.7 Million EUR | 30.37% |
| 2020 | 200.73 Million EUR | 6.31% |
| 2019 | 188.82 Million EUR | 63.87% |
| 2018 | 115.22 Million EUR | 8.0% |
| 2017 | 106.69 Million EUR | 2.16% |
| 2016 | 104.44 Million EUR | 5.43% |
| 2015 | 99.06 Million EUR | -3.68% |
| 2014 | 102.85 Million EUR | 12.45% |
| 2013 | 91.45 Million EUR | -4.65% |
| 2012 | 95.91 Million EUR | -15.93% |
| 2011 | 114.08 Million EUR | 4.9% |
| 2010 | 108.75 Million EUR | 15.18% |
| 2009 | 94.41 Million EUR | 40.53% |
| 2008 | 67.19 Million EUR | 11.55% |
| 2007 | 60.23 Million EUR | 19.92% |
| 2006 | 50.22 Million EUR | -100.0% |
| 2005 | 3350.26 Billion EUR | 42431.24% |
| 2004 | 7.87 Billion EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 254.88 Million EUR | -0.59% |
| 2024 Q2 | 374.56 Million EUR | 46.96% |
| 2023 Q4 | 256.39 Million EUR | -7.13% |
| 2023 FY | 256.39 Million EUR | -28.25% |
| 2023 Q1 | 316.39 Million EUR | -11.45% |
| 2023 Q2 | 380.04 Million EUR | 20.12% |
| 2023 Q3 | 276.08 Million EUR | -27.35% |
| 2022 Q1 | 319.16 Million EUR | 21.96% |
| 2022 FY | 357.32 Million EUR | 36.54% |
| 2022 Q2 | 391.21 Million EUR | 22.58% |
| 2022 Q4 | 357.32 Million EUR | 8.55% |
| 2022 Q3 | 329.18 Million EUR | -15.86% |
| 2021 Q1 | 194.03 Million EUR | -3.34% |
| 2021 Q4 | 261.7 Million EUR | 12.79% |
| 2021 FY | 261.7 Million EUR | 30.37% |
| 2021 Q2 | 240.38 Million EUR | 23.88% |
| 2021 Q3 | 232.03 Million EUR | -3.47% |
| 2020 FY | 200.73 Million EUR | 6.31% |
| 2020 Q4 | 200.73 Million EUR | 4.41% |
| 2020 Q3 | 192.25 Million EUR | 0.35% |
| 2020 Q2 | 191.58 Million EUR | 0.65% |
| 2020 Q1 | 190.34 Million EUR | 0.81% |
| 2019 Q4 | 188.82 Million EUR | 36.47% |
| 2019 Q1 | 133.21 Million EUR | 15.61% |
| 2019 FY | 188.82 Million EUR | 63.87% |
| 2019 Q2 | 149.81 Million EUR | 12.46% |
| 2019 Q3 | 138.36 Million EUR | -7.64% |
| 2018 FY | 115.22 Million EUR | 8.0% |
| 2018 Q3 | 115.05 Million EUR | -3.42% |
| 2018 Q2 | 119.13 Million EUR | 9.6% |
| 2018 Q1 | 108.69 Million EUR | 1.87% |
| 2018 Q4 | 115.22 Million EUR | 0.15% |
| 2017 Q4 | 106.69 Million EUR | 8.66% |
| 2017 FY | 106.69 Million EUR | 2.16% |
| 2017 Q3 | 98.19 Million EUR | -13.02% |
| 2017 Q2 | 112.88 Million EUR | 0.86% |
| 2017 Q1 | 111.92 Million EUR | 7.16% |
| 2016 Q1 | 91.41 Million EUR | -7.72% |
| 2016 Q2 | 103.09 Million EUR | 12.77% |
| 2016 Q3 | 92.31 Million EUR | -10.46% |
| 2016 Q4 | 104.44 Million EUR | 13.14% |
| 2016 FY | 104.44 Million EUR | 5.43% |
| 2015 Q4 | 99.06 Million EUR | -0.8% |
| 2015 Q2 | 105.32 Million EUR | 8.87% |
| 2015 Q3 | 99.86 Million EUR | -5.19% |
| 2015 Q1 | 96.74 Million EUR | -5.94% |
| 2015 FY | 99.06 Million EUR | -3.68% |
| 2014 Q3 | 90.83 Million EUR | -5.85% |
| 2014 Q2 | 96.48 Million EUR | 11.38% |
| 2014 Q4 | 102.85 Million EUR | 13.22% |
| 2014 FY | 102.85 Million EUR | 12.45% |
| 2014 Q1 | 86.62 Million EUR | -5.29% |
| 2013 Q4 | 91.45 Million EUR | -4.6% |
| 2013 Q3 | 95.86 Million EUR | -0.12% |
| 2013 Q2 | 95.98 Million EUR | 3.75% |
| 2013 Q1 | 92.51 Million EUR | -3.55% |
| 2013 FY | 91.45 Million EUR | -4.65% |
| 2012 Q1 | 100.15 Million EUR | -12.21% |
| 2012 Q4 | 95.91 Million EUR | 2.75% |
| 2012 Q3 | 93.34 Million EUR | -5.73% |
| 2012 FY | 95.91 Million EUR | -15.93% |
| 2012 Q2 | 99.02 Million EUR | -1.14% |
| 2011 Q3 | 106.85 Million EUR | -2.54% |
| 2011 FY | 114.08 Million EUR | 4.9% |
| 2011 Q4 | 114.08 Million EUR | 6.77% |
| 2011 Q2 | 109.64 Million EUR | 1.93% |
| 2011 Q1 | 107.56 Million EUR | -1.09% |
| 2010 FY | 108.75 Million EUR | 15.18% |
| 2010 Q4 | 108.75 Million EUR | 0.0% |
| 2009 FY | 94.41 Million EUR | 40.53% |
| 2008 FY | 67.19 Million EUR | 11.55% |
| 2007 FY | 60.23 Million EUR | 19.92% |
| 2006 FY | 50.22 Million EUR | -100.0% |
| 2005 FY | 3350.26 Billion EUR | 42431.24% |
| 2004 FY | 7.87 Billion EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -380.987% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -2575.74% |
| SQZ Biotechnologies Company | 50.03 Million USD | -412.38% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -253.783% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -334.456% |
| Mesoblast Limited | 188.44 Million USD | -36.056% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -6557.018% |
| Genus plc | 485 Million USD | 47.136% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -4288.27% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -10089.053% |
| Marizyme, Inc. | 26.67 Million USD | -861.137% |
| ContraFect Corporation | 32.53 Million USD | -688.141% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -6647.105% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -12840.441% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -6598.369% |
| Intellipharmaceutics International Inc. | 12 Million USD | -2035.024% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -2076.819% |
| MultiCell Technologies, Inc. | 1617.67 USD | -15849238.864% |
| Accustem Sciences Inc. | 1.07 Million USD | -23656.554% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -231.18% |
| EV Biologics, Inc. | 2.11 Million USD | -12022.063% |
| Q BioMed Inc. | 8.13 Million USD | -3052.489% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -209.146% |
| Neon Bloom, Inc. | 1.22 Million USD | -20809.092% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -4882.282% |
| Biomind Labs Inc. | 1.49 Million USD | -17008.498% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | -5.046% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -1293.165% |
| Skye Bioscience, Inc. | 14.07 Million USD | -1721.957% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -12654.896% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -180335.624% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -2608.558% |
| IMV Inc. | 37.93 Million USD | -575.906% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -127383.641% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -4362.2% |
| GB Sciences, Inc. | 5.41 Million USD | -4632.576% |
| Alpha Cognition Inc. | 7.16 Million USD | -3478.48% |
| HST Global, Inc. | 593.59 Thousand USD | -43092.895% |
| CSL Limited | 18.62 Billion USD | 98.623% |
| Halberd Corporation | 728.71 Thousand USD | -35083.658% |
| Enzolytics Inc. | 365.26 Million USD | 29.808% |
| Resverlogix Corp. | 67.39 Million USD | -280.423% |
| Affymax, Inc. | 8.87 Million USD | -2790.204% |
| SYBLEU INC | 681.41 Thousand USD | -37526.227% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -30468.763% |
| argenx SE | 444.95 Million USD | 42.378% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -242.218% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -14858.576% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -2053.977% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -6895.321% |
| AVAX Technologies, Inc. | 3.99 Million USD | -6319.789% |
| Zenith Capital Corp. | 27.56 Thousand USD | -929893.834% |
| Genscript Biotech Corporation | 1.32 Billion USD | 80.663% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -107331.679% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -6765.8% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -37558.225% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -115.958% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -2735.484% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -382977.59% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -17781.092% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -410.087% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -9355.16% |
| BioStem Technologies, Inc. | 15.9 Million USD | -1512.043% |
| ONE Bio Corp. | 27.49 Million USD | -832.469% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -55073.349% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -934504.309% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -20261.454% |
| Agentix Corp. | 2.51 Million USD | -10112.483% |
| LadRx Corporation | 2.2 Million USD | -11551.295% |
| Cell Source, Inc. | 15.8 Million USD | -1522.032% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -573530.75% |
| Regen BioPharma, Inc. | 5.45 Million USD | -4597.839% |
| Regen BioPharma, Inc. | 5.45 Million USD | -4597.839% |
| NovAccess Global Inc. | 7.86 Million USD | -3161.656% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -936.086% |
| Itoco Inc. | 1.65 Million USD | -15409.17% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -12397.289% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -4138.552% |
| Kadimastem Ltd | 3.5 Million USD | -7215.256% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -60718.184% |
| CytoDyn Inc. | 127.89 Million USD | -100.471% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -613287.88% |
| Mobile Lads Corp. | 1.31 Million USD | -19419.649% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -16268.346% |
| Qrons Inc. | 1.48 Million USD | -17122.258% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -2221.261% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -31600.285% |
| Rebus Holdings, Inc. | 5.24 Million USD | -4791.072% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -4101.803% |
| International Stem Cell Corporation | 5.27 Million USD | -4758.632% |
| Bioxytran, Inc. | 3.24 Million USD | -7790.137% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -40869.369% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -5453.023% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -525.402% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -1051.538% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -12558.815% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -4580.358% |
| Neutra Corp. | 973.52 Thousand USD | -26236.144% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -783.646% |
| PureTech Health plc | 125.58 Million USD | -104.16% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -6724.101% |
| IXICO plc | 1.9 Million USD | -13392.137% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -1148.916% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -148.142% |
| CSL Limited | 18.62 Billion USD | 98.623% |
| Cellectis S.A. | 249.36 Million USD | -2.815% |